AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15743154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines
Number of subjects: 0
Study 15743154 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 14750898 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF) after high-dose chemotherapy with stem cell support
Number of subjects: 33
Study 14750898 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF) in the treatment of established chemotherapy-induced febrile neutropenia
Number of subjects: 33
Study 14750898 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 33
Study 16617547 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated postpartum health-care program at CSLH
Number of subjects: 0
Study 16617547 — intervention group
Group type: COMPARATOR
Intervention: Public clinic services
Number of subjects: 0
Study 8595995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (high dosage)
Number of subjects: 0
Study 8595995 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 8595995 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study 1883256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (up to 300 mg/d)
Number of subjects: 520
Study 1883256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 1883256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 520
Study 6347211 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepathrombin‐50,000‐Salbe
Number of subjects: 27
Study 6347211 — intervention group
Group type: COMPARATOR
Intervention: Ointment base
Number of subjects: 27
Study 30621746 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose TNF inhibitors (adalimumab, etanercept, infliximab, golimumab)
Number of subjects: 126
Study 30621746 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose TNF inhibitors (approximately half the standard dose)
Number of subjects: 126
Study 30621746 — intervention group
Group type: COMPARATOR
Intervention: Full-dose TNF inhibitors
Number of subjects: 126
Study 30621746 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose TNF inhibitors
Number of subjects: 126
Study 30278544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 0.15 mg/kg before anesthesia induction
Number of subjects: 80
Study 30278544 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 27716215 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic real-time feedback (KRTF) group
Number of subjects: 0
Study 27716215 — intervention group
Group type: COMPARATOR
Intervention: Traditional method group (G1)
Number of subjects: 0
Study 24252058 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 79-4980 (35 IU kg(‐1))
Number of subjects: 131
Study 24252058 — intervention group
Group type: COMPARATOR
Intervention: rFVIII-FS (25 IU kg(‐1))
Number of subjects: 131
Study 21517925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 5 mg (fasted)
Number of subjects: 24
Study 21517925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg (fasted)
Number of subjects: 24
Study 21517925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 20 mg (fasted)
Number of subjects: 24
Study 21517925 — intervention group
Group type: COMPARATOR
Intervention: Mitiglinide (all doses)
Number of subjects: 24
Study 21057743 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-strengthening moisturizer (5% urea)
Number of subjects: 53
Study 21057743 — intervention group
Group type: COMPARATOR
Intervention: No treatment (no medical or non-medicated preparations)
Number of subjects: 53
Study 17951496 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/d of Synergy (inulin-type fructans)
Number of subjects: 48
Study 17951496 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin control
Number of subjects: 48
Study 15699296 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75‐225 mg/d)
Number of subjects: 440
Study 15699296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐50 mg/d)
Number of subjects: 440
Study 15699296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 12050266 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg, n = 10)
Number of subjects: 31
Study 12050266 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1275 mg, n = 8)
Number of subjects: 31
Study 12050266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Flutamide + Metformin, n = 13)
Number of subjects: 31
Study 10471871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (Cleocin)
Number of subjects: 36
Study 10471871 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (Augmentin) and ticarcillin/clavulanate (Timentin)
Number of subjects: 36
Study 10471871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8543489 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 81
Study 8543489 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 81
Study 2043514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous aspiration and lavage of the gallbladder followed by intra‐lumenal instillation of 500 mg ampicillin (PALA)
Number of subjects: 40
Study 2043514 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with 500 mg of ampicillin every 6 hours for 5 days (Control)
Number of subjects: 40
Study 2043514 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA
Number of subjects: 40
Study 2043514 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 6458250 — intervention group
Group type: EXPERIMENTAL
Intervention: Corsets with lumbar supports
Number of subjects: 0
Study 6458250 — intervention group
Group type: COMPARATOR
Intervention: Corsets without lumbar supports
Number of subjects: 0
Study 31840204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanzo Cu‐NiTi archwire
Number of subjects: 50
Study 31840204 — intervention group
Group type: COMPARATOR
Intervention: NT3 superelastic NiTi archwire
Number of subjects: 50
Study 31840204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both archwires
Number of subjects: 50
Study 31840204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014-in. archwire
Number of subjects: 50
Study 28833074 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 35 kg/m2
Number of subjects: 151996
Study 27644162 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for a minimum of 1 month
Number of subjects: 53
Study 27644162 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic-hypoxia
Number of subjects: 53
Study 27644162 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 53
Study 24797207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses (chickpeas, yellow peas, navy beans, lentils)
Number of subjects: 0
Study 24797207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 0
Study 24797207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpeas
Number of subjects: 0
Study 21820829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-modulated ECG-gated CT angiography
Number of subjects: 60
Study 19236986 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous strategy
Number of subjects: 12
Study 19236986 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric strategy
Number of subjects: 12
Study 19236986 — intervention group
Group type: COMPARATOR
Intervention: Asymmetric-2 strategy
Number of subjects: 12
Study 19236986 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric-1 strategy
Number of subjects: 12
Study 17306974 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 1224
Study 17306974 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 1224
Study 15094937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 73
Study 12377352 — intervention group
Group type: EXPERIMENTAL
Intervention: 192Ir multiple seed trains
Number of subjects: 0
Study 12377352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-volume histograms (DVH) for an eccentric seed train
Number of subjects: 0
Study 9848300 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 52
Study 9848300 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/d
Number of subjects: 52
Study 9848300 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 52
Study 9848300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7926342 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 45
Study 7926342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections (4‐6 times daily)
Number of subjects: 45
Study 7926342 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (twice daily)
Number of subjects: 45
Study 7926342 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 45
Study 2573264 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily (AT 50)
Number of subjects: 40
Study 2573264 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily (AT 100)
Number of subjects: 40
Study 2573264 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice a day (Prop)
Number of subjects: 40
Study 2573264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 173257 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (5,500 RHD CO‐60)
Number of subjects: 196
Study 173257 — intervention group
Group type: COMPARATOR
Intervention: Primary operation (no preoperative irradiation)
Number of subjects: 196
Study 173257 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Number of subjects: 196
Study 173257 — intervention group
Group type: COMPARATOR
Intervention: Primary operation
Number of subjects: 196
Study 31559845 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-channel phased array head coil
Number of subjects: 300
Study 31559845 — intervention group
Group type: COMPARATOR
Intervention: 6-channel dS Flex M surface coil
Number of subjects: 300
Study 31409636 — intervention group
Group type: EXPERIMENTAL
Intervention: GAM (gamification-based training)
Number of subjects: 489
Study 31409636 — intervention group
Group type: COMPARATOR
Intervention: EVA (evaluation-based training)
Number of subjects: 489
Study 31409636 — intervention group
Group type: COMPARATOR
Intervention: VFC (visual feedback complementary training)
Number of subjects: 489
Study 31409636 — intervention group
Group type: COMPARATOR
Intervention: TC (traditional complementary training)
Number of subjects: 489
Study 28228317 — intervention group
Group type: EXPERIMENTAL
Intervention: SAXA-MET (5 mg/2,000 mg)
Number of subjects: 38
Study 28228317 — intervention group
Group type: COMPARATOR
Intervention: MET (2,000 mg)
Number of subjects: 38
Study 28228317 — intervention group
Group type: COMPARATOR
Intervention: SAXA (5 mg)
Number of subjects: 38
Study 28228317 — intervention group
Group type: EXPERIMENTAL
Intervention: SAXA-MET
Number of subjects: 38
Study 28228317 — intervention group
Group type: EXPERIMENTAL
Intervention: SAXA-MET and SAXA
Number of subjects: 38
Study 26028918 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin
Number of subjects: 95
Study 26028918 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 95
Study 24074421 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based suturing/knot-tying curriculum
Number of subjects: 21
Study 24074421 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 21
Study 24074421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention MS4 vs Boot-Camp MS4
Number of subjects: 21
Study 24074421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention MS4 vs PGY-1 interns
Number of subjects: 21
Study 24074421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention MS4 vs PGY-2 residents
Number of subjects: 21
Study 22108474 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Oxide Ointment
Number of subjects: 0
Study 22108474 — intervention group
Group type: COMPARATOR
Intervention: Best management (control)
Number of subjects: 0
Study 19370045 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.6 g of whey protein + 3.4 g of leucine (W+L)
Number of subjects: 0
Study 19370045 — intervention group
Group type: COMPARATOR
Intervention: Flavored water (PL)
Number of subjects: 0
Study 16761701 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 31
Study 16761701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15378556 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg divalproex sodium extended-release (divalproex-ER)
Number of subjects: 39
Study 15378556 — intervention group
Group type: COMPARATOR
Intervention: 500 mg divalproex sodium extended-release (divalproex-ER)
Number of subjects: 39
Study 11387490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contrast agent (Levovist, 300 mg/mL, 1 mL/min)
Number of subjects: 26
Study 11387490 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound contrast agent (USCA)
Number of subjects: 26
Study 11387490 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of USCA
Number of subjects: 26
Study 9409267 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) administered intravenously for 6 hours
Number of subjects: 12
Study 9409267 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously for 6 hours
Number of subjects: 12
Study 8494374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive aluminum‐magnesium hydroxide antacid regimen (Maalox TC) administered at multiple time points relative to enoxacin infusion.
Number of subjects: 12
Study 8494374 — intervention group
Group type: COMPARATOR
Intervention: Intravenous enoxacin (400 mg) administered without antacid treatment.
Number of subjects: 12
Study 3317784 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema, 2 mg/100 ml
Number of subjects: 64
Study 3317784 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone disodium phosphate enema, 31.25 mg/100 ml
Number of subjects: 64
Study 3317784 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema
Number of subjects: 64
Study 3317784 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone enema
Number of subjects: 64
Study 30429920 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device (LVAD) patients presenting to the ED
Number of subjects: 349
Study 30429920 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for presentation to the ED
Number of subjects: 349
Study 30429920 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-specific presentations
Number of subjects: 349
Study 30429920 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for device-specific presentations
Number of subjects: 349
Study 30429920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump thrombosis
Number of subjects: 349
Study 28211882 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2 mg) administered as three monthly intravitreal injections followed by two bi-monthly injections and a final examination at week 28.
Number of subjects: 46
Study 25413264 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus financial reinforcement
Number of subjects: 29
Study 25413264 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 29
Study 25413264 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 29
Study 23279731 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic questionnaire sent via e-mail at 8PM asking about SCL visual performance
Number of subjects: 48
Study 23279731 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic questionnaire on weekdays (Sunday through Thursday)
Number of subjects: 48
Study 23279731 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic questionnaire on weekends (Friday and Saturday)
Number of subjects: 48
Study 23279731 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 23 and older
Number of subjects: 48
Study 21464563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted wound treatment (UAW)
Number of subjects: 67
Study 21464563 — intervention group
Group type: COMPARATOR
Intervention: Surgical wound debridement (WD)
Number of subjects: 67
Study 18493214 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids (LCPUFAs) supplementation (AA: 20-30 mg daily, DHA: 14-21 mg daily)
Number of subjects: 37
Study 18493214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16566900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.5 mg)
Number of subjects: 22
Study 16566900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15799928 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 152
Study 15799928 — intervention group
Group type: COMPARATOR
Intervention: Conventional on-pump coronary artery bypass grafting (CCAB)
Number of subjects: 152
Study 11273502 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga lifestyle intervention
Number of subjects: 42
Study 11273502 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 42
Study 9089582 — intervention group
Group type: EXPERIMENTAL
Intervention: liposome-adjuvanted vaccine
Number of subjects: 77
Study 9089582 — intervention group
Group type: COMPARATOR
Intervention: control subvirion vaccine
Number of subjects: 77
Study 1337623 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin once daily for 3 days (L3)
Number of subjects: 703
Study 1337623 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin once daily for 7 days (L7)
Number of subjects: 703
Study 1337623 — intervention group
Group type: COMPARATOR
Intervention: 400 mg norfloxacin twice daily for 7 days (N7)
Number of subjects: 703
Study 2858246 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling about drinking habits from a nurse
Number of subjects: 156
Study 2858246 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 156
Study 31479209 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided group (CYP2C19 genetic testing)
Number of subjects: 2488
Study 31479209 — intervention group
Group type: COMPARATOR
Intervention: Standard-treatment group (ticagrelor or prasugrel)
Number of subjects: 2488
Study 29601443 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination (DRE)
Number of subjects: 233
Study 29601443 — intervention group
Group type: COMPARATOR
Intervention: No DRE
Number of subjects: 233
Study 27465112 — intervention group
Group type: COMPARATOR
Intervention: Education on routine hygiene measures
Number of subjects: 223
Study 27465112 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus decolonization without reminders (intranasal mupirocin ointment twice daily for 7 days and chlorhexidine gluconate on the first and last day)
Number of subjects: 223
Study 27465112 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus decolonization with reminders (daily telephone call or text message reminders)
Number of subjects: 223
Study 27465112 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with decolonization protocol
Number of subjects: 223
Study 24612260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/ondansetron group
Number of subjects: 237
Study 24612260 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-only group
Number of subjects: 237
Study 22472069 — intervention group
Group type: EXPERIMENTAL
Intervention: PKRP combined with 2 μm laser vaporization
Number of subjects: 120
Study 22472069 — intervention group
Group type: COMPARATOR
Intervention: PKRP only
Number of subjects: 120
Study 19726422 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 266
Study 19726422 — intervention group
Group type: COMPARATOR
Intervention: travoprost 0.004%
Number of subjects: 266
Study 17043094 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (weekly): gemcitabine 1000 mg/m2 and paclitaxel 100 mg/m2 on days 1 and 8 of a 21-day cycle
Number of subjects: 100
Study 17043094 — intervention group
Group type: COMPARATOR
Intervention: Arm A (three-weekly): gemcitabine 1000 mg/m2 on days 1 and 8 and paclitaxel 200 mg/m2 on day 1 of a 21-day cycle
Number of subjects: 100
Study 16253098 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth scaling and root planing (SRP)
Number of subjects: 60
Study 16253098 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and 400 mg systemically administered metronidazole (MET) three times per day for 10 days
Number of subjects: 60
Study 16253098 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and professional supragingival plaque removal (PP) every week for 3 months
Number of subjects: 60
Study 16253098 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and MET plus PP
Number of subjects: 60
Study 12411355 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoke alarms distributed and installed on request
Number of subjects: 20050
Study 10640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Static flexor and extensor thresholds
Number of subjects: 12
Study 10640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal flexor and extensor torques
Number of subjects: 12
Study 10640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Active torque production
Number of subjects: 12
Study 10640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocally organized agonist and antagonist muscle activity
Number of subjects: 12
Study 10640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive muscle coactivation
Number of subjects: 12
Study 10640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Spasticity measured at rest
Number of subjects: 12
Study 8795759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/ml)
Number of subjects: 28